-
Sep 26, 2017
Newly Published Data Supports Avelas Biosciences’ Investigational Ratiometric Activatable Fluorescent Peptide AVB-620 in Intraoperative Tumor Detection
Read more
-
Sep 14, 2017
Avelas Biosciences’ AVB-620 Shows Sensitive In Vivo Visualization of Breast Cancer in Journal Publication
Read more
-
Aug 03, 2017
Avelas Biosciences Doses First Patient in Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
Read more
-
Jun 13, 2017
Avelas Biosciences to Participate in JMP Securities Life Sciences Conference
Read more
-
May 04, 2017
Avelas Biosciences Appoints Steven Chen as Chief Medical Officer
Read more
-
Mar 29, 2017
Avelas Biosciences to Present at Needham & Company 16th Annual Healthcare Conference
Read more
-
Mar 14, 2017
Avelas Biosciences Appoints Alexey Vinogradov, Ph.D., to Board of Directors
Read more
-
Mar 07, 2017
Avelas Biosciences to Present at 29th Annual Roth Conference
Read more
-
Dec 08, 2016
Avelas Presents Phase 1b Clinical Trial Data for AVB-620 at 2016 San Antonio Breast Cancer Symposium
Read more
« Previous Page — Next Page »
